Phase 1a/1b Evaluation of KM-023 in Healthy Volunteers and Patients with Olmsted Syndrome

The primary objective of this study is to evaluate the safety and tolerability of **KM-023** in both healthy volunteers and patients with **Olmsted syndrome**. This is clinically relevant as it aims to establish the initial safety profile of the investigational product, which is crucial for determining its potential therapeutic application in treating Olmsted syndrome, a rare genetic disorder characterized by palmoplantar keratoderma and periorificial keratotic plaques. The study does not specify any secondary objectives.

The clinical trial involves a total of **three participants** diagnosed with **Olmsted syndrome**, a rare genetic disorder. The study population includes both male and female subjects, with an age range that spans from children to adults. Participants were selected based on specific criteria, although the principal inclusion criteria were not provided by the sponsor. The trial includes a vulnerable population, indicating that special considerations are in place to ensure the safety and ethical treatment of participants. Information regarding the general health status, lifestyle considerations such as diet, physical activity, or habits, was not disclosed by the sponsor.

The clinical trial is a **Phase 1** study designed to evaluate the safety and tolerability of KM-023 in both healthy volunteers and patients diagnosed with **Olmsted syndrome**. The trial is structured as a randomized, double-blind, and controlled study, ensuring that neither the participants nor the investigators are aware of the treatment assignments, thereby minimizing bias. The estimated duration of the trial spans from June 2, 2025, to February 15, 2026, encompassing both the recruitment and study phases.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This visit is crucial for determining participant suitability based on predefined inclusion and exclusion criteria. Following successful screening, participants will be randomized into treatment groups. Throughout the trial, several follow-up visits will be scheduled to monitor the participants' health, assess the drug's safety profile, and collect necessary data. These visits are integral to ensuring participant safety and the collection of high-quality data. The trial will conclude with an end-of-study visit, where final assessments are conducted, and participants are debriefed.

The expected length of participant involvement in the study is approximately eight months, depending on individual response and adherence to the study protocol. Conditions that may lead to early termination from the study include adverse reactions to the investigational product, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is conducted under strict ethical guidelines and regulatory standards to ensure the safety and well-being of all participants.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided dataset. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on June 2, 2025, with an estimated completion date of February 15, 2026. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize various parameters such as **biomarker** levels or symptom improvement scores to gather initial efficacy data. The methods and schedule for measuring, collecting, and analyzing these parameters are not specified, but they generally involve validated scales, laboratory tests, or patient-reported outcomes at predetermined timepoints. The trial will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy data collected.